| scholarly article | Q13442814 |
| P2093 | author name string | B Lamarca | |
| P2860 | cites work | Eicosanoids in preeclampsia | Q28166550 |
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study | Q28281936 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops | Q33225347 | ||
| 17-Hydroxyprogesterone blunts the hypertensive response associated with reductions in uterine perfusion pressure in pregnant rats | Q33607461 | ||
| Effects of 17-hydroxyprogesterone on tumor necrosis factor-alpha-induced hypertension during pregnancy | Q33607465 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study | Q33947553 | ||
| Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 | ||
| Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. | Q34514153 | ||
| Vitamins C and E and the risks of preeclampsia and perinatal complications | Q34518082 | ||
| Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. | Q34702420 | ||
| Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia | Q35681821 | ||
| Oxidative stress and preeclampsia: rationale for antioxidant clinical trials | Q35869763 | ||
| Abnormal placentation and the syndrome of preeclampsia | Q35941005 | ||
| Role of the renin-angiotensin system in the pathogenesis of preeclampsia | Q36064478 | ||
| B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? | Q36106119 | ||
| Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. | Q36123039 | ||
| Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction | Q36228832 | ||
| Preeclampsia: recent insights | Q36288757 | ||
| Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens | Q36291176 | ||
| Endothelial dysfunction in pre-eclampsia. | Q36749162 | ||
| Granulocyte colony-stimulating factor for the induction of T-cell tolerance. | Q36882397 | ||
| Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin | Q61845423 | ||
| Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia | Q64377002 | ||
| The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice | Q64377179 | ||
| Maternal plasma level of endothelin is increased in preeclampsia | Q67973452 | ||
| Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure | Q73567364 | ||
| Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet | Q78009520 | ||
| Maternal fetal/placental interactions and abnormal pregnancy outcomes | Q79372322 | ||
| Difference in neutrophil superoxide generation during pregnancy between preeclampsia and essential hypertension | Q80125849 | ||
| Questionable role of the angiotensin II receptor subtype 1 autoantibody in the pathogenesis of preeclampsia | Q80336129 | ||
| Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women | Q80470716 | ||
| Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis | Q80824106 | ||
| Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies | Q81236313 | ||
| Hypertension during pregnancy: a disorder begging for pathophysiological support | Q81397976 | ||
| Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression | Q81411178 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| Angiogenesis in rheumatoid arthritis | Q82627687 | ||
| Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia | Q82705098 | ||
| Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis | Q83207457 | ||
| Targeting effector memory T-cells with Kv1.3 blockers | Q36894674 | ||
| Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. | Q37447371 | ||
| Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats | Q37449704 | ||
| Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade | Q37459545 | ||
| Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? | Q40268212 | ||
| Importance of prostaglandins in hypertension during reduced uteroplacental perfusion pressure | Q41284596 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| Association of maternal endothelial dysfunction with preeclampsia | Q43553727 | ||
| Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. | Q43576536 | ||
| Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction | Q43744794 | ||
| Enhanced thromboxane synthesis during chronic reductions in uterine perfusion pressure in pregnant rats | Q44130345 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species | Q44743355 | ||
| Cytochrome P-450 inhibition attenuates hypertension induced by reductions in uterine perfusion pressure in pregnant rats | Q44752496 | ||
| L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure | Q44760481 | ||
| Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia | Q44902467 | ||
| TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas | Q45102738 | ||
| Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia | Q45112360 | ||
| Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women | Q45158743 | ||
| Aldosterone, inflammation, and preeclampsia | Q45256329 | ||
| Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia | Q46332630 | ||
| Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. | Q46339760 | ||
| Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study | Q46343093 | ||
| Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia | Q46433836 | ||
| System y+ arginine transport and NO production in peripheral blood mononuclear cells in pregnancy and preeclampsia | Q46847905 | ||
| Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion | Q46877931 | ||
| Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies | Q46878600 | ||
| Insulin resistance in preeclampsia | Q46919162 | ||
| Protective effect of vascular endothelial growth factor/vascular permeability factor 165 and 121 on glomerular endothelial cell injury in the rat. | Q47349254 | ||
| Implication of an AGT haplotype in a multigene association study with pregnancy hypertension | Q47364068 | ||
| Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women | Q47770771 | ||
| Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. | Q50514586 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. | Q51139503 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. | Q51569218 | ||
| Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. | Q51914188 | ||
| Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. | Q52087250 | ||
| Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. | Q52933863 | ||
| Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. | Q52936000 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. | Q53491305 | ||
| Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. | Q54661322 | ||
| Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia | Q56981931 | ||
| Dysregulation of the Circulating and Tissue-Based Renin-Angiotensin System in Preeclampsia | Q56981959 | ||
| Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 | Q57105968 | ||
| High Blood Pressure in Pregnancy and Coronary Calcification | Q57910195 | ||
| In Preeclampsia, the Circulating Factors Capable of Altering In Vitro Endothelial Function Precede Clinical Disease | Q58035998 | ||
| Changes in Endothelial Function Precede the Clinical Disease in Women in Whom Preeclampsia Develops | Q61830910 | ||
| Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia | Q61845360 | ||
| P433 | issue | 2 | |
| P921 | main subject | arterial hypertension | Q41861 |
| pre-eclampsia | Q61335 | ||
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 105-120 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Minerva Ginecologica | Q15752699 |
| P1476 | title | The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia | |
| P478 | volume | 62 |
| Q35151065 | 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model |
| Q37507162 | Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q35130793 | CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy |
| Q47688833 | Continued Investigation Into 17-OHPC: Results From the Preclinical RUPP Rat Model of Preeclampsia |
| Q56996369 | Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia |
| Q61844895 | ELABELA plasma concentrations are increased in women with late-onset preeclampsia |
| Q34533218 | Endothelin-1 is not a Mechanism of IL-17 Induced Hypertension during Pregnancy. |
| Q36340302 | Epicardial fat tissue thickness in preeclamptic and normal pregnancies |
| Q33740993 | Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia |
| Q36351174 | Four Pathways Involving Innate Immunity in the Pathogenesis of Preeclampsia |
| Q92133961 | Human chorionic gonadotropin and risk of pre-eclampsia: prospective population-based cohort study |
| Q36244980 | Hypertension in response to IL-6 during pregnancy: role of AT1-receptor activation |
| Q36997267 | IL-10 supplementation increases Tregs and decreases hypertension in the RUPP rat model of preeclampsia |
| Q36178540 | IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy |
| Q35581520 | IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate? |
| Q37139722 | Identifying immune mechanisms mediating the hypertension during preeclampsia |
| Q38707968 | Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia |
| Q90434468 | Local angiotensin-(1-7) administration improves microvascular endothelial function in women who have had preeclampsia |
| Q36062460 | Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia |
| Q26746049 | No Hypertensive Disorder of Pregnancy; No Preeclampsia-eclampsia; No Gestational Hypertension; No Hellp Syndrome. Vascular Disorder of Pregnancy Speaks for All |
| Q39423454 | Pathophysiology and Current Clinical Management of Preeclampsia |
| Q64119466 | Placenta Transcriptome Profiling in Intrauterine Growth Restriction (IUGR) |
| Q35542826 | Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia |
| Q26800272 | Preeclampsia: long-term consequences for vascular health |
| Q33983395 | Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy |
| Q38691672 | Proliferation of endogenous regulatory T cells improve the pathophysiology associated with placental ischaemia of pregnancy |
| Q90311066 | Red-Osier Dogwood Extracts Prevent Inflammatory Responses in Caco-2 Cells and a Caco-2 BBe1/EA.hy926 Cell Co-Culture Model |
| Q45848306 | Reduced uterine perfusion pressure T-helper 17 cells cause pathophysiology associated with preeclampsia during pregnancy |
| Q57167914 | Residual Vascular Dysfunction in Women with a History of Preeclampsia |
| Q34785813 | Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia |
| Q45350029 | Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia |
| Q38664824 | The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study |
| Q33834419 | The role of inflammation in the pathology of preeclampsia |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
Search more.